Analyzing Cost of Revenue: Perrigo Company plc and Geron Corporation

Analyzing Cost of Revenue: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding the cost of revenue is crucial for evaluating a company's financial health. Perrigo Company plc and Geron Corporation, two prominent players, offer a fascinating contrast in their financial journeys from 2014 to 2023.

Perrigo Company plc: A Steady Climb

Perrigo has consistently maintained a robust cost of revenue, averaging around $2.96 billion annually. Despite minor fluctuations, the company saw a peak in 2020, with costs reaching approximately $3.25 billion, reflecting a 24% increase from 2014. This steady growth underscores Perrigo's resilience and strategic market positioning.

Geron Corporation: A Volatile Path

In contrast, Geron Corporation's cost of revenue has been more volatile, with a significant spike in 2023, reaching $123.74 million, a staggering 1,290% increase from 2021. This dramatic rise highlights the company's dynamic approach and potential for future growth, albeit with higher risk.